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TO THE EDITOR
Preexposure prophylaxis (PrEP) with oral
administration of an antiretroviral is
a potential method for preventing
acquisition of HIV. A controlled trial in
men who have sex with men (the
iPrEx trial) showed that daily oral use
of tenofovir disoproxil fumarate-
emtricitabine (TDF-FTC; Truvada)
reduced transmission rates by 44%
(Grant et al., 2010). In addition, the
HIV Prevention Trial Network (HPTN)
052 trial recently confirmed that
antiretroviral treatment leads to 96%
reduction in transmission among
HIV-negative heterosexual partners of
HIV-positive individuals (Cohen et al.,
2011). Similar trials, however, with
TDF-FTC (the FEM-PrEP trial) or TDF
alone (the VOICE trial) were stopped
because of poor outcomes (van der
Straten et al., 2012). Different results
among various trials, which used
identical antiretroviral regimens, could
be explained by varying compliance
with drug use and/or varying drug
concentration and activity within the
exposed tissue (Patterson et al., 2011).
Langerhans cells (LCs) are CCR5þ
dendritic cells located within genital
skin and mucosal epithelium (Leder-
man et al., 2006). In female rhesus
macaques exposed intravaginally
to simian immunodeficiency virus, up
to 90% of initially infected target cells
were LCs (Hu et al., 2000). Ex vivo
experiments with human foreskin
explants show that epidermal LCs are
target cells for HIV, providing a likely
explanation for why circumcision
greatly reduces the probability of acqui-
ring HIV (Ganor et al., 2010). LCs also
express CD4 and CCR5, but not CXCR4,
within the tissue and demonstrate the
distinctive characteristics of emigrating
from tissue to draining lymph nodes
in order to interact with T cells after
contact with pathogens (Kawamura
et al., 2000). Indeed, epidermal LCs
are readily infected ex vivo with R5
HIV, but not with X4 HIV, and
promote high levels of infection upon
interaction with cocultured CD4þ T
cells (Kawamura et al., 2000; Ogawa
et al., 2013). Thus, LCs probably have
an important role in disseminating HIV
soon after exposure to virus.
Epidemiologic observations have
found that the majority of HIV strains
isolated from patients soon after initial
infection are R5 HIV strains (i.e., they
utilize CCR5; Lederman et al., 2006).
Not surprisingly, individuals with
homozygous defects in CCR5 are
largely protected from sexually acqui-
ring HIV (Lederman et al., 2006). In
addition, three different CCR5-binding
topically applied compounds protected
female macaques from sexually
acquiring simian/human immunodefi-
ciency virus: the N-terminally modified
chemokine analog PSC-RANTES, the
small-molecule inhibitor CMPD167,
and maraviroc (MVC) (Lederman et al.,
2006; Veazey et al., 2010). In addition
to topical application to vaginal
mucosa, oral delivery of CMPD167
protected macaques from vaginal
simian/human immunodeficiency virus
challenge (Veazey et al., 2005). Given
these data, orally administered MVC
may prove to be particularly important
in PrEP regimens, although its ability to
prevent HIV acquisition is unknown.
In the current study, 20 healthy volun-
teers were randomly divided into four
equal groups; they received 300 mg of
MVC orally twice daily for 1, 2, 3, or
14 days. To obtain epidermal tissues, all
subjects underwent suction blistering of
the skin before and 2 hours after the last
MVC dose. All subjects had plasma
and semen collected 2 hours after their
last dose. MVC concentrations in serum,
semen, and epidermal tissues were
determined by using the liquid chroma-
tography– mass spectometry method, as
described previously (Takahashi et al.,
2010). Mean concentration±SD in the
epidermis was 21.91±13.80, 23.36±
13.28, and 31.54±20.61 nM for
individuals taking drug for 1, 2, or
3 days (n¼5 for each), respectively.
MVC concentrations tended to be
higher with a longer dosing period.
Consistent with recent data showing
high levels of MVC in genital tissue
(Dumond et al., 2009), these results
indicate that MVC rapidly distributes
into the skin at high concentrations.
In addition, MVC was detected in
semen of all subjects (Supplementary
Figure S1 online).
To understand how HIV traverses skin
and genital mucosa, an ex vivo model
was developed whereby resident
LCs within epithelial tissue explants
are exposed to HIV and then allowed
to emigrate from tissue, thus mimicking
conditions that occur after mucosal
exposure to HIV (Kawamura et al.,
2000; Ogawa et al., 2013). In this
model, although relatively few producti-
vely infected LCs are identified, these
cells induce high levels of HIV infection
when cocultured with resting auto-
logous CD4þ T cells (Kawamura et al.,
2000). In preliminary experiments, HIV
infection of LCs, as well as subsequent
virus transmission from emigrated
LCs to cocultured CD4þ T cells, was
decreased in a dose-dependent manner
when skin explants were pretreated with
various concentrations of MVC before
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HIV exposure (Supplementary Figure S2
online), similar to experiments reported
earlier with PSC-RANTES (Kawamura
et al., 2004).
Next, the epithelial tissue explants
were collected from study subjects
after oral treatment with MVC
(Supplementary Materials and Methods
online). Importantly, oral MVC pretreat-
ment for either 1 or 2 days partially
inhibited subsequent ex vivo HIVBa-L
infection of LCs within epithelial tissue,
whereas MVC administration for either
3 or 14 days completely blocked
LCs from ex vivo HIVBa-L infection
(Figure 1). These data demonstrate the
importance of the length of MVC dosing
period before HIV exposure. MVC treat-
ment also consistently prevented HIVBa-L
transmission from LCs to cocultured
CD4þ T cells (Figure 2). Furthermore,
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Figure 1. Oral administration of maraviroc (MVC) protects epidermal Langerhans cells (LCs) from ex vivo R5 HIV infection. Skin explants were isolated from
healthy individuals who had received oral MVC (300 mg twice daily) for the indicated periods of time. These tissues were exposed to HIVBa-L (a, c), HIVAD8, or
HIVJR-FL (b, c) and then cultured for 3 days. Emigrated LCs were collected and assessed for HIV infection by flow cytometry. Representative FACS analyses of
CD11c and p24 mAb double-stained cells are shown (a, b). Percent MVC inhibition of LC infection with HIVBa-L (J), HIVAD8 (n), or HIVJR-FL (&) was calculated
as described in the text (c). *Po0.05; **Po0.01. Mean values obtained from different donors are shown as horizontal marks.
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Figure 2. Oral administration of maraviroc (MVC) blocks viral transmission from HIV-exposed Langerhans cells (LCs) to cocultured CD4þ T cells. Skin
explants isolated from healthy individuals who had received oral MVC (300 mg twice daily) for the indicated periods of time were exposed to HIVBa-L (a, c),
HIVAD8, or HIVJR-FL (b, c), as described in Figure 1. Emigrated LCs were cocultured with autologous CD4
þ T cells, and culture supernatants were assessed for p24
content by ELISA. Representative ELISA results are shown (a, b). Percent MVC inhibition of HIVBa-L (K), HIVAD8 (m), or HIVJR-FL (’) transmission to cocultured
CD4þ T cells was calculated as described in the Methods (c). *Po0.05; **Po0.01. Mean values obtained from different donors are shown as horizontal marks.
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MVC administration for 3 days blocked
ex vivo virus infection of LCs as well as
subsequent virus transmission when dif-
ferent R5 HIV strains, HIVAD8 and
HIVJR-FL, were utilized for an additional
six subjects (n¼3 for each strain,
Figures 1 and 2). These data demon-
strate that oral administration of MVC
for at least 3 days is capable of fully
protecting HIV infection of LCs within
epithelial tissue.
These experiments provide perhaps
the best proof-of-concept test for MVC
as a potential PrEP drug, as it would
be unethical to expose MVC-treated
volunteers to HIV in vivo. As proven
here, orally delivered MVC rapidly distri-
butes to skin and functionally acts to block
infection of relevant target cells, LCs,
supporting randomized controlled trials
of MVC as a PrEP therapy for individuals
at high risk of becoming infected with HIV
through sexual exposure.
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TO THE EDITOR
Punctate palmoplantar keratoderma
(punctate PPK or PPKP) is a rare
autosomal dominant disorder of kera-
tinization. Three variants of this disease
have been described; PPKP1 (OMIM
x148600, Buschke–Fischer–Brauer type)
is characterized by the progressive devel-
opment of discrete areas of hyperkerato-
sis on the palms and soles, followed by
more extensive diffuse hyperkeratosis on
the pressure-bearing areas of plantar skin.
Linkage analyses of families affected
by PPKP1 have previously identified aAccepted article preview online 6 June 2013; published online 11 July 2013
Abbreviations: AAGAB, gene encoding alpha- and gamma-adaptin-binding protein p34; bp, base pair;
OMIM, Online Mendelian Inheritance in Man; PPK(P), (punctate) palmoplantar keratoderma; RTK,
receptor tyrosine kinase
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